BioNxt Solutions Inc.
BNXT
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -77.08% | 190.70% | -99.32% | -97.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -77.08% | 190.70% | -99.32% | -97.53% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -77.08% | 190.70% | -99.32% | -97.53% |
| SG&A Expenses | 80.43% | -17.83% | 60.48% | -74.43% | 0.00% |
| Depreciation & Amortization | -123.84% | -48.42% | -53.19% | -59.17% | -53.01% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.96% | -47.33% | 21.06% | -67.56% | -8.69% |
| Operating Income | -28.36% | 47.04% | -20.16% | 64.74% | -2.83% |
| Income Before Tax | -17.86% | 45.29% | -2.67% | 59.43% | -5.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.86% | 48.84% | -2.67% | 59.43% | -5.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.86% | 48.84% | -2.67% | 59.43% | -5.51% |
| EBIT | -28.36% | 47.04% | -20.16% | 64.74% | -2.83% |
| EBITDA | -28.98% | 47.84% | -23.60% | 64.90% | -5.01% |
| EPS Basic | -11.21% | 52.33% | 10.38% | 63.48% | 9.32% |
| Normalized Basic EPS | -2.99% | 39.78% | 10.61% | 63.39% | 9.46% |
| EPS Diluted | -11.21% | 52.33% | 10.38% | 63.48% | 9.32% |
| Normalized Diluted EPS | -2.99% | 39.78% | 10.61% | 63.39% | 9.46% |
| Average Basic Shares Outstanding | 5.86% | 7.41% | 14.37% | 11.54% | 16.43% |
| Average Diluted Shares Outstanding | 5.86% | 7.41% | 14.37% | 11.54% | 16.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |